| Grant number: | 26/17536-0 |
| Support Opportunities: | Scholarships in Brazil - Scientific Initiation |
| Start date: | November 01, 2026 |
| End date: | October 31, 2027 |
| Field of knowledge: | Biological Sciences - Pharmacology - Neuropsychopharmacology |
| Principal Investigator: | Daniela Baptista de Souza |
| Grantee: | Marcos Aurélio Santos Moreno |
| Host Institution: | Faculdade de Ciências Farmacêuticas (FCFAR). Universidade Estadual Paulista (UNESP). Campus de Araraquara. Araraquara , SP, Brazil |
| Associated research grant: | 22/04387-6 - Sex differences and oxytocinergic transmission impact on chronic pain in animal models and humans, AP.JP |
Abstract Chronic pain is a condition affecting 20% ¿¿of the global population, with a higher prevalence among women. Pain is influenced by biological, psychological, and sociocultural factors and is frequently associated with psychopathologies such as anxiety and depression. In this context, oxytocin is a neuropeptide that plays a central role in both pain modulation and the regulation of stress responses. To investigate the functioning of these pathways, DREADD chemogenetic technology in *Oxytocin-Ires-Cre* transgenic mice has become an essential tool. However, the primary ligand used, Clozapine-N-Oxide (CNO), undergoes metabolic back-conversion into clozapine, causing non-specific effects on the animals' locomotion and anxiety levels. A lack of standardization regarding dosages and sex-based differences limits the reproducibility of scientific data in current literature. Addressing this gap, the objective of this project is to determine the optimal CNO dose for safe chemogenetic modulation in this strain, establishing a concentration that does not elicit non-specific effects in either sex. To this end, male and female mice will be divided into groups receiving either saline solution or CNO (at doses of 0.1, 1.0, and 10 mg/kg). The methodology will involve inducing prolonged pain using the latent hyperalgesia model. Throughout the protocol, experiments will be conducted to assess mechanical hypersensitivity (von Frey test) and the affective component of pain (Facial Pain Scale), alongside the Elevated Plus-Maze test to evaluate anxiety-like behaviors and general motor activity. Physiological indicators of well-being (body weight and coat quality) will also be monitored. It is expected that establishing this dose-response curve will allow for the identification of a CNO dose that avoids non-specific effects, thereby ensuring the reliability of results during subsequent tests using DREADD technology. (AU) | |
| News published in Agência FAPESP Newsletter about the scholarship: | |
| More itemsLess items | |
| TITULO | |
| Articles published in other media outlets ( ): | |
| More itemsLess items | |
| VEICULO: TITULO (DATA) | |
| VEICULO: TITULO (DATA) | |